Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) EPS (Weighted Average and Diluted): 2020-2024

Historic EPS (Weighted Average and Diluted) for Foghorn Therapeutics (FHTX) over the last 5 years, with Dec 2024 value amounting to -$1.58.

  • Foghorn Therapeutics' EPS (Weighted Average and Diluted) rose 19.35% to -$0.25 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.13, marking a year-over-year increase of 41.15%. This contributed to the annual value of -$1.58 for FY2024, which is 32.48% up from last year.
  • As of FY2024, Foghorn Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.58, which was up 32.48% from -$2.34 recorded in FY2023.
  • Foghorn Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at -$1.58 for FY2024, and its period low was -$6.23 during FY2020.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$2.34 (2023), whereas its average is -$2.18.
  • Data for Foghorn Therapeutics' EPS (Weighted Average and Diluted) shows a peak YoY skyrocketed of 56.18% (in 2021) over the last 5 years.
  • Over the past 5 years, Foghorn Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$6.23 in 2020, then surged by 56.18% to -$2.73 in 2021, then grew by 4.03% to -$2.62 in 2022, then climbed by 10.69% to -$2.34 in 2023, then skyrocketed by 32.48% to -$1.58 in 2024.